{"prompt": "['Administrative reasons', '5.7 Clinical Criteria for Early Trial Termination', 'Early trial termination will be the result of the criteria specified below:', '1. Quality or quantity of data recording is inaccurate or incomplete', '2. Poor adherence to protocol and regulatory requirements', '3. Incidence or severity of adverse drug reaction in this or other studies indicates a potential', 'health hazard to participants', '4. Plans to modify or discontinue the development of the study drug', 'In the event of Merk decision to no longer supply study drug, ample notification will be', 'provided so that appropriate adjustments to participant treatment can be made.', '35']['6.0 TRIAL FLOW CHART', '6.1', 'Study Flow Chart', 'Post-', 'Long-term', 'Treatment', 'Follow-up', 'Trial Phase:', 'Pre-treatment Phase', 'Treatment Phaseb', 'Phase', 'Phase', 'Screening', 'Baseline', 'Treatment Cycle/Title:', '(Visit 1)a,b', '(Visit 2) a,b', '1', '2', '3', '4', 'Within 14', 'days of last', 'Every 12', 'dose of', 'weeks +/- 14', 'Day:', '-28 to 1', '-3 to 1', '1', '8', '15', '22', '29', '36', '43', '50', '57', '64', '71', '78', 'lenvatinib', 'days', 'Administrative Procedures', 'Informed Consent', 'X', 'Inclusion/Exclusion Criteria', 'X', 'X', 'Demographics and Medical History', 'X', 'Prior and Concomitant Medication', 'X', 'X', 'X', 'Xd', 'Review', 'Assessment of Trial Compliance', 'X', 'X', 'X', 'X', 'Lenvatinib Administration', 'Throughout (daily)', 'Pembrolizumab Administration', 'X', 'X', 'X', 'Clinical Procedures/Assessments', 'Review Adverse Events', 'X (throughout)', 'X', 'X', 'Full Physical Examination', 'X', 'Focused Physical Exam', 'X', 'X', 'X', 'Vital Signs, Height and Weighte', 'X', 'X', 'ECOG Performance Status', 'X', 'X', 'X', 'MUGA or echocardiogram', 'X', 'Xg', 'Xg', '12-lead EKG', 'X', 'X', 'X', 'Sarcopenia Assessmenth', 'X', 'X', 'Quality of Life Assessment\u00b9', 'X', 'X', 'Frailty Assessment', 'X', 'X', '36']['Post-', 'Long-term', 'Treatment', 'Follow-up', 'Trial Phase:', 'Pre-treatment Phase', 'Treatment Phaseb', 'Phase', 'Phase', 'Screening', 'Baseline', 'Treatment Cycle/Title:', '(Visit 1 )a,b', '(Visit 2) a,b', '1', '2', '3', '4', 'Within 14', 'days of last', 'Every 12', 'dose of', 'weeks +/- 14', 'Day:', '-28 to 1', '-3 to 1', '1', '8', '15', '22', '29', '36', '43', '50', '57', '64', '71', '78', 'lenvatinib', 'days', 'Laboratory Procedures/Assessments: analysis performed by LOCAL laboratory', 'Pregnancy Test - Urine or serum B-', 'X', 'X', 'X', 'X', 'HCGK', 'PT/INR and aPTT', 'X', 'X', 'X', 'Clinical laboratory tests\u00b9', 'X', 'X', 'X', 'Liver enzymes11', 'X', 'Urinalysis1,0', 'X', 'X', 'X', 'X', 'T3, FT4 and TSH', 'X', 'X', 'X', 'Efficacy Measurements', 'Tumor Imaging', 'MRI brainp', 'X', 'CT chest', 'X', 'X', 'CT or MRI abdomen/pelvist', 'X', 'X', 'X', 'Survival', 'X (throughout)', 'X', 'Xc', 'Tumor Biopsies/Archival Tissue Collection/Correlative Studies Blood', 'Archival or Newly Obtained Tissue', 'X', 'Collection', 'Nephrectomy', 'Xt,u', 'Correlative Studies Blood Collection', 'X', 'X', 'XY', 'Stool sample for microbiome', 'X', 'X', 'a.', 'The screening period extends from Day -28 to Day 1 Subjects must be screened within 28 days prior to Cycle 1/Day 1. The screening assessment can serve as the', 'baseline assessment, if performed within 72 h before Cycle 1/Day 1. The baseline assessment can be performed from Day -3 to Cycle 1/Day 1 (prior to the', 'first', 'dose', 'of', 'study drug). Informed consent may be obtained up to 8 weeks prior to the start of study drug.', 'b.', 'Efforts should be made to conduct study visits on the day scheduled (=3 days). Treatment cycles will be counted continuously regardless of dose interruptions.', 'Clinical', 'laboratory assessments may be conducted anytime within 72 h prior to the scheduled visit, unless otherwise specified.', '37']\n\n###\n\n", "completion": "END"}